NCT05767723View on ClinicalTrials.gov

Platelet Sub-study of the Neomindset Trial

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

May 30, 2025

Study Completion Date

June 30, 2025

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel

Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)

DRUG

Monotherapy: Ticagrelor alone OR Prasugrel alone

Ticagrelor alone (90 mg twice daily) OR Prasugrel alone (10 mg once daily)

Trial Locations (1)

Unknown

Hospital Israelita Albert Einstein, São Paulo

All Listed Sponsors
lead

Hospital Israelita Albert Einstein

OTHER